학술논문

Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
Document Type
article
Source
Lupus. 31(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Autoimmune Disease
Lupus
Adult
Benchmarking
Cognitive Dysfunction
Humans
Lupus Erythematosus
Systemic
Neuropsychological Tests
Rheumatology
systemic lupus erythematosus
cognitive impairment
CART analysis
ANAM
lupus
screening
Arthritis & Rheumatology
Clinical sciences
Language
Abstract
ObjectiveWe previously demonstrated the utility of the Automated Neuropsychological Assessment Metrics (ANAM) for screening cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) and developed composite indices for interpreting ANAM results. Our objectives here were to provide further support for the ANAM's concurrent criterion validity against the American College of Rheumatology neuropsychological battery (ACR-NB), identify the most discriminatory subtests and scores of the ANAM for predicting CI, and provide a new approach to interpret ANAM results using Classification and Regression Tree (CART) analysis.Methods300 adult SLE patients completed an adapted ACR-NB and ANAM on the same day. As per objectives, six models were built using combinations of ANAM subtests and scores and submitted to CART analysis. Area under the curve (AUC) was calculated to evaluate the ANAM's criterion validity compared to the adapted ACR-NB; the most discriminatory ANAM subtests and scores in each model were selected, and performance of models with the highest AUCs were compared to our previous composite indices; decision trees were generated for models with the highest AUCs.ResultsTwo models had excellent AUCs of 86 and 89%. Eight most discriminatory ANAM subtests and scores were identified. Both models demonstrated higher AUCs against our previous composite indices. An adapted decision tree was created to simplify the interpretation of ANAM results.ConclusionWe provide further validity evidence for the ANAM as a valid CI screening tool in SLE. The decision tree improves interpretation of ANAM results, enhancing clinical utility.